http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2164117-C2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_72e2a023c558b51d973e979033b70490
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_716283b4d47c7564eba0b73a2e3c1704
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-007
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-008
filingDate 1999-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2001-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_594ec8c954c8b9cd49b98e1e1720aef9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d27b4e6bb86235ece5496bb64a2a81b1
publicationDate 2001-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RU-2164117-C2
titleOfInvention Method for treating secondary glaucoma cases
abstract FIELD: medicine. SUBSTANCE: method involves carrying out ciliary body contraction from the side of posterior chamber using YAG-laser. Erbium-YAG endolaser radiation is applied. The ciliary body is fixed to sclera with endolaser coagulation device. EFFECT: high quantity anatomic adjacency of ciliary body to sclera; reduced risk of ciliary body and vascular eye coat detachment.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2447868-C2
priorityDate 1999-02-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419569951
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419577455
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5416
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID23980

Total number of triples: 19.